Lund, Sweden, December 11, 2012 - Active Biotech's (NASDAQ OMX NORDIC: ACTI) partner Teva Pharmaceutical Industries Ltd. will today Tuesday, December 11, 2012 at 12:00 p.m. ET (6:00 p.m. CET) host an investor meeting. Teva has a license to develop and commercialize Active Biotech's molecule laquinimod, and this molecule may be discussed during the meeting.
For further information please see www.tevapharm.com.
Active Biotech AB (publ)
Tomas Leanderson
President & CEO
For further information, please contact:
Hans Kolam, CFO
Phone: +46 (0)46 19 20 44
E-mail: hans.kolam@activebiotech.com
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in or entering pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, TASQ for prostate cancer as well as ANYARA for use in cancer targeted therapy, primarily of renal cell cancer. In addition, laquinimod is in Phase II development for Crohn's and Lupus. An additional project in clinical development is the orally administered compound 57-57 for Systemic Sclerosis. Please visit www.activebiotech.com for more information.
Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00
Active Biotech is obligated to publish the information contained in this press release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication 8:30 a.m. CET on December 11, 2012.
